Health

Dapagliflozin Cuts Heart Failure in Diabetes

[ad_1] CHICAGO —  Dapagliflozin (Farxiga/Forxiga, AstraZeneca) showed a nonsignificant trend toward a reduced rate of major adverse cardiac events (MACE) but significantly reduced hospitalization for heart failure in the DECLARE-TIMI 58 trial in …

Read More »